Updated:
Nexalin Technology
Mark White's Nexalin Technology produces non-invasive neurostimulation devices for treatment-resistant mental health conditions, trading publicly on the...
Nexalin Technology
Nexalin Technology operates as a medical device developer concentrating on non-invasive brain stimulation technologies. The firm's core product is a transcranial alternating current stimulation device designed to treat anxiety, depression, and insomnia without the systemic side effects of medication. Its regulatory footprint spans multiple geographies, with marketing clearances that include a Class II medical device listing from the Chinese National Medical Products Administration. The company trades publicly in the United States. The firm's commercial strategy relies on clinician adoption and direct wholesale distribution rather than a traditional pharmaceutical sales model. Its technology uses a proprietary waveform delivered via a headset, a departure from implantable or magnetic stimulation alternatives. The addressable market is patients with treatment-resistant mental health conditions. The company has historically pursued a hub-and-spoke model, providing centralized equipment for use across clinical networks. As a micro-cap entity, the company raises capital through public equity offerings rather than traditional venture rounds. In the 24 months leading into 2026, the firm remained an SEC-reporting issuer with shares listed on the Nasdaq Capital Market. Its operating scale is small, with resources directed toward clinical validation studies and expanding regulatory approvals in international markets. Nexalin's structure as a publicly traded device manufacturer — not a privately held portfolio company — means its strategic decisions play out in quarterly filings. The firm is accountable to retail and institutional shareholders rather than a single-family capital base, which shapes a posture oriented toward incremental clinical milestones rather than speculative moonshots.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
—
Corporate office
—
Principals
Mark White
Chief Executive Officer
Sector focus
Frequently asked questions
What technology does Nexalin Technology produce?
Nexalin develops a transcranial alternating current stimulation device that delivers a proprietary waveform through a headset. The device is non-invasive and designed to treat anxiety, depression, and insomnia. It received Class II medical device clearance in China, among other jurisdictions. The approach seeks to avoid the systemic side effects associated with psychiatric medications.
Is Nexalin Technology a publicly traded company?
Yes, Nexalin Technology trades on the Nasdaq Capital Market under the ticker NXL. The company is an SEC-reporting micro-cap entity. It funds operations and clinical work through periodic public equity offerings. Its public status means investment and operational details are available in quarterly and annual SEC filings.
How is Nexalin's device different from other neurostimulation treatments?
Nexalin uses transcranial alternating current stimulation rather than implantable devices or transcranial magnetic stimulation. The device is worn externally as a headset. It delivers a proprietary waveform that the company argues penetrates deeper brain structures. This non-pharmaceutical, outpatient model aims to serve the large population of patients who are treatment-resistant to standard antidepressants.
In which markets does Nexalin have regulatory clearance?
Nexalin has historically focused on international markets including China, where it holds a Class II medical device listing from the National Medical Products Administration. It also pursues clearances in other Asian and Middle Eastern jurisdictions. The company's US regulatory strategy involves working toward FDA marketing authorization, though the specific status evolves across reporting periods.
Who runs investment decisions at Nexalin Technology?
Strategic and capital-allocation decisions rest with Chief Executive Officer Mark White and the board of directors. As a publicly traded micro-cap company, material transactions require board approval and are subject to SEC disclosure obligations. The firm does not operate as a family office and has no single-family capital sponsor directing investment policy.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: